Spatio-Genetic and Phenotypic Modelling Elucidates Resistance and Re-Sensitisation to Treatment in Heterogeneous Melanoma

Arran Hodgkinson^{a,b,*}, Laurent Le Cam^b, Dumitru Trucu^c, Ovidiu Radulescu^a

^a*Dynamique des Interaction Membranaires Normales et Pathologique, Université de Montpellier, Montpellier, France*

^b*Institut de Recherche en Cancérologie de Montpellier, Montpellier, France*

^c*Division of Mathematics, University of Dundee, Dundee, Scotland*

Abstract

Although novel targeted therapies have significantly improved the overall survival of patients with advanced melanoma, understanding and combatting drug resistance remains a major clinical challenge. Using partial differential equations, we describe the evolution of a cellular population through time, space, and phenotype dimensions, in the presence of various drug species. We then use this framework to explore models in which resistance is attained by either mutations (irreversible) or plasticity (reversible). Numerical results suggest that punctuated evolutionary assumptions are more consistent with results obtained from murine melanoma models than gradual evolution. Furthermore, in the context of an evolving tumour cell population, sequencing the treatment, for instance applying immunotherapy before BRAF inhibitors, can increase treatment effectiveness. However, drug strategies which showed success within a spatially homogeneous tumour environment were unsuccessful under heterogeneous conditions, suggesting that spatio-environmental heterogeneity may be the greatest challenge to tumour therapies. Plastic metabolic models are additionally capable of reproducing the characteristic resistant tumour volume

*Corresponding author

Email addresses: arran.hodgkinson@umontpellier.fr (Arran Hodgkinson), laurent.lecam@inserm.fr (Laurent Le Cam), trucu@maths.dundee.ac.uk (Dumitru Trucu), ovidiu.radulescu@umontpellier.fr (Ovidiu Radulescu)

curves and predicting re-sensitisation to secondary waves of treatment observed in patient derived xenograft (PDX) melanomas treated with MEK and BRAF inhibitors. Nevertheless, secondary relapse due to a pre-adapted subpopulation, remaining after the first wave of treatment, results in a more rapid development of resistance. Our model provides a framework through which tumour resistance can be understood and would suggest that carefully phased treatments may be able to overcome the development of long-term resistance in melanoma.

Keywords: Systems Biology, Cancer Evolution, Melanoma, Heterogeneity, Spatio-Structural Models

2018 MSC: 00-01, 99-00

1. Introduction

1.1. Mathematical Background

The vast majority of existing, quantitative models of drug resistance are based on discrete stochastic mechanisms of evolution, which fail to take into account the intermediary stages and continuous nature of phenotypic development [1, 2, 3, 4].

Of the continuous models, several provide insights into the dynamics of evolutionary processes but are often restricted to single cell or non-spatial population models [5, 6], necessarily containing space averaging assumptions (well-stirred reactor hypothesis). Of these models, few take into account the prominent theory of PE [7] or have the depth to explain its significance in the context of drug resistance. Herein, we present a continuous spatio-structuro-temporal model to describe both the dynamics of the population of evolving tumour cells as a whole and how targeted therapy can produce resistant strains. We further use the model to recommend future strategies for prevention of this process.

One recent study has further looked at the effect of diffusion-based drug gradients on the effective outcome of population diversity and heterogeneity [8]. This heterogeneity is evident in the biological literature but is yet to be explained by existing mathematical models.

20 A new addition to the variety of available bio-mathematical modelling frame-
works has been spatio-structuro-temporal modelling, introduced by Domschke
et al. [9] and later subjected to higher-dimensional simulation and numerical
analysis [10]. This allows one to represent not only the spatial aspects of a pop-
ulation but also, simultaneously, some underlying aspect of its structure, giving
25 one more insight into the co-evolution of these characteristics. This model has
since been extended further [11] but has not yet been used to look at intrinsic
properties of tumours, with respect to their systematic resistance to targeted
therapies.

1.2. Biological Motivation

30 Current mathematical abstractions of the biological paradigm for drug resis-
tance characterise the biological system as existing in a series of discrete states;
perhaps susceptible cells, cells with resistance to drug 1, cells with resistance to
drug 2, and cells with resistance to both drugs. This discrete interpretation (Fig.
1a), however, is not born out in experimentation since the observation of cells
35 under the influence of any given drug will demonstrate a spectrum of response
patterns. The common assumption that cells instantaneously realign themselves
to a ‘resistant’ phenotype also appears to presuppose the eventual survival of
such cells. Moreover, gene expression levels of a given cell population submitted
to treatment do not appear to exhibit strong qualitative differentiation and are
40 more accurately described as a continuum.

Therefore, we take an alternative approach to modelling wherein we consider
the cellular population as a single population which is continuously variable
through some structural dimension, as opposed to previous discretised descrip-
tions (Fig. 1b). The structural dimension can be understood as a set of variables
45 characterizing the cell state at a molecular and/or phenotypic level. Within the
cell population, subgroups are differentially sensitive to drugs and may exhibit
differing proliferative and migratory behaviours, more generally. This gives us
extended scope to model the more nuanced aspects of the heterogeneous cellular
pathways towards resistance and invasion of the surrounding tissue in cancer.

Figure 1: Diagrams indicative of (a) a discrete paradigm, wherein a cell undergoes instantaneous and complete transitions between healthy and resistant states, and (b) a continuous paradigm, in which a cell undergoes a continuous alteration between two extreme healthy and resistant states and is capable of inhabiting all points between these two extremes.

50 In the proceeding section (Section 2), we present a general mathematical approach to modelling biological cancer systems whose spatial and structural dynamics are coupled and introduce the various terms within this system. Moving forward we provide a possible application for this model in the study of systems who develop resistance through the sequential mutation of particular oncogenes

55 and the effects of BRAF inhibitors and immunotherapies on this development (Section 3). The results for this mutational model are then studied in detail, with particular interest given to the effects of the order and methodology of treatment and heterogeneity in the tumour environment (Section 4). Next, we provide a second possible application for this model in the study of systems

60 whose metabolism of certain nutrients, particularly the metabolism of glucose through glycolysis or oxidative phosphorylation, shapes their response to drugs, resulting in a plastically resistant system (Section 5). We then explore results coming from this metabolically plastic system with a specific view to understanding the effect of treatment of spatial and metabolic heterogeneity and the

65 resulting responses to treatment (Section 6). Finally we discuss the results from both of these systems in the wider contrast and the ramifications of this current study (Section 7).

2. Presentation of the General Model

Herein, we present a mathematical model that contains

- 70 (1) One cell species function, denoted $c(t, x, y)$, depending on time t , space x , and structure y , representing a continuous distribution of mutational or metabolic phenotypes of cancerous cells:
 - (1a) The structure variables y describe either mutational or metabolic status of the cell. In general, cells will be able to move in either
75 a positive or negative mutational or metabolic direction, depending on the paradigm in question and possibly based on environmental factors.
 - (1b) The mutational or metabolic alterations taking place within this cellular species will fundamentally alter its behaviour and the nature of
80 its interaction with the micro- and macro-environments,
- (2) A function representing the extracellular nutritional environment (ECNE), denoted $v(t, x)$; including the collagen matrix, distributed fibronectin, and vasculature, assumed to be proportional to one another as explored in the mathematical model of Gatenby [12],
- 85 (3) A vector valued function representing the concentrations of diffusible molecular species, denoted $\bar{m}(t, x)$, including metabolites, metallo-proteases, chemo-attractants or chemo-repellents, which will have the ability to mediate the interactions among the variables $c(t, x, y)$, and ECNE, $v(t, x)$,
- (4) A vector valued function representing the concentrations of some medicines,
90 denoted $\bar{p}(t, x)$, of detriment to the growth of certain of the cancerous species.

In the following, we describe the main steps for building the model. Details of the mathematical approach to establishing this system of equations may be found in Appendix A.

95 Mathematically, we employ a multi-dimensional framework which allows for the coupling of spatial dynamics, in x , with other biological or biochemical dynamics in the cells themselves, which we call structural dynamics and denote by y . Then we can use an existing mathematical framework [9, 11] to deduce that the change in cell density $c(t, x, y)$ is given by the continuity equation

$$\frac{\partial}{\partial t} c(t, x, y) = \nabla_x \cdot \underbrace{F(c, v, \bar{m})}_{\text{Spatial Flux}} + \nabla_y \cdot \underbrace{G(y, c, v, \bar{m}, \bar{p})}_{\text{Structural Flux}} + \underbrace{S(y, c, v, \bar{m}, \bar{p})}_{\text{Source}}, \quad (1)$$

100 where $\bar{a} \cdot \bar{b}$ stands for the dot product of vectors $\bar{a}$ and $\bar{b}$.

Through this, we recognise that the function $F(c, v, \bar{m})$ describes the movement of the cellular population in space, whilst $G(y, c, v, \bar{m}, \bar{p})$ describes the structural change in the cellular population, and $S(y, c, v, \bar{m}, \bar{p})$ describes the overall change in the population or the number of cells entering or leaving the system through mitosis or apoptosis/necrosis, respectively.

2.1. Spatial flux of the cellular population

Begin by denoting ρ the collective spatial volume of the cellular and ECNE populations, defined as

$$\rho(c, v) := \int_{\mathcal{P}} c(t, x, y) dy + v(t, x). \quad (2)$$

110 where $\mathcal{P}$ is the structural domain. This $\rho(c, v)$ then represents a measure of the total volume occupied by the cellular and ECNE population, together, and will allow us to model the unoccupied volume into which the cells and ECNE may grow. Further, we assume that the cell spatial dynamics are given by diffusion, chemo- and haptotactic directed transport, as in Chaplain *et al.* [13]. Diffusive dynamics correspond to autonomous stochastic motility in spatial cellular dynamics whilst chemo- and haptotaxis correspond to directed motion evoked through attraction to biochemicals or substrate components, respectively. The diffusion, chemotactic, and haptotactic rate constants are then given by D_c , $\bar{\chi}_m$,

and χ_v , respectively. This may be mathematically represented as the following
 120 term:

$$F(c, v, \bar{m}) = D_c \nabla_x c + c(1 - \rho(c, v)) (\nabla_x (\bar{\chi}_m \cdot \bar{m}) + \nabla_x \chi_v v) . \quad (3)$$

As in [13], the chemo- and haptotactic fluxes are volume constrained and vanish when the collective spatial volume reaches a maximum capacity that, without loss of generality, is considered equal to one. A simple way to take this
 125 constraint into account is to consider that these two fluxes are proportional to $1 - \rho$, where $\rho(c, v)$ is defined as in (2).

2.2. Structural flux of the cellular population

The structural flux is the sum of two terms, an advection flux and a structural
 130 diffusion flux, corresponding to biased and unbiased evolution in the structure space, respectively.

In order to define the advection flux we introduce the function $\Psi(y, \bar{m}, \bar{p})$, representing the normalized structural velocity, who is dependent upon the population's structural distribution, the local nutrient concentration and the local
 135 concentration of drugs. Given some maximal rate for the population's velocity through the structural dimension, r_μ , the structural velocity shall be given by $r_\mu \Psi(y, \bar{m}, \bar{p})$, where the normalized structural velocity satisfies $|\Psi(y, \bar{m}, \bar{p})| \leq 1$. The structural advection flux term is the product of the structural velocity and the cell distribution density and reads

$$G_a(y, c, v, \bar{m}, \bar{p}) = r_\mu \Psi(y, \bar{m}, \bar{p}) c . \quad (4)$$

140 In this paper, we shall consider one cellular system in which behaviour is adapted through the accumulation of consecutive mutation (Section 3) and one in which a cell may plastically evolve its behavioural phenotype through metabolic reprogramming dynamics (Section 5). For each of these scenarios, it will be necessary to define a distinct and biologically relevant form for the function $\Psi(y, \bar{m}, \bar{p})$.

145 Diffusion in structural space can occur as the result of a stress, following
a change of environmental conditions. In order to adapt to the environment,
the population tends to diversify its behaviour which leads to an increase in
spread of the y -space cell distribution. This diversification of behavior can be
phenomenologically described by a structural diffusion matrix $\Sigma(y, \bar{m}, \bar{p})$. The
150 structural diffusion flux is supposed to satisfy Fick's law and reads

$$G_d(y, c, v, \bar{m}, \bar{p}) = -\Sigma(y, \bar{m}, \bar{p}) \nabla_y c. \quad (5)$$

Although structural diffusion is possible both in a mutational and a metabolic
context, in this paper we will consider it only in relation to metabolic remodel-
ing.

The total structural flux is the sum of the structural advection and structural
155 diffusion terms and reads

$$G(y, c, v, \bar{m}, \bar{p}) = G_a(y, c, v, \bar{m}, \bar{p}) + G_d(y, c, v, \bar{m}, \bar{p}). \quad (6)$$

2.3. Source/Sink terms for the cellular population

The growth of any given cell will be dependent on an assortment of intracel-
160 lular and environmental factors, including its structural state, y ; the availability
of nutrients, $\bar{m}$; and the volume surrounding the cell which has not yet been
filled, $\rho(c, v)$. Therefore, we write the growth rate of the population generi-
cally as $\Phi(y, \bar{m}, c, v)$ such that we may define its particular dynamics for the
considered scenario. It is important to remember that this term accounts only
165 for growth of the cell population and not the negative growth caused by the
introduction of drugs.

It is clear that, since drugs are typically designed to exploit a particular
behaviour or dependence of a given cancerous population, its effectiveness will
be dependent upon the current structural state of the cell, y . We account for
170 the effect of drugs on the cellular population, then, by taking the product of
the cellular apoptosis rate, the drugs' effectiveness functions, and the respective

local drug concentrations $\delta_c \bar{p}(t, x) \bar{f}(y)$. Multiplying this by the cellular concentration, itself, will yield the degradative sink. As such, the entire source/sink term may be written mathematically as

$$S(y, c, v, \bar{m}, \bar{p}) = \Phi_c(y, \bar{m}, c, v)c - \delta_c \bar{f}(y) \cdot \bar{p}c. \quad (7)$$

175

Since, in this particular study, we are interested in the effects of structural heterogeneity on the success of a given cancer population the normalized structural velocity, $\Psi(y, \bar{m}, \bar{p})$; structurally-dependent growth function, $\Phi_c(y, \bar{m}, c, v)$; and the structurally-dependent drug effectiveness function, $\bar{f}(y)$, are of most interest. Their dependence on structural considerations makes them of particular
180 relevance to the particular situation in which they are applied and so all 3 terms will be specifically defined for the mutational (Section 3) or phenotypic (Section 5) considerations, respectively.

185 2.4. Dynamics in the ECNE, molecular, and drug species

The dynamics of the ECNE, $v(t, x)$, will be described simply, without spatial dynamics, as growth given by the ECNE remodelling function $\Phi_v(c, v)$ and the degradation of the ECNE by chemical species. The degradation constant vector will then be given by $\bar{\delta}_v = [\delta_{v, m_1}, \delta_{v, m_2}, \dots]^T$ and will have the same number
190 of components as there are chemical species. For any i^{th} chemical species that does not degrade the ECNE, the degradation constant $\delta_{v, m_i} = 0$. Our PDE for the ECNE dynamics is then given by

$$\frac{\partial v}{\partial t} = \Phi_v(c, v)v - \bar{\delta}_v \cdot \bar{m}v. \quad (8)$$

Spatial dynamics of the molecular species vector, $\bar{m}(t, x)$, are given simply by
195 diffusion with its rate vector $\bar{D}_m$. Chemical species are then produced either by the ECNE, and connected network of capillaries, $v(t, x)$, or the cellular species, $c(t, x, y)$, with rates dependent on y such that its general expression may be given by the function $\bar{\Phi}_m(y, \bar{m}, c, v)$. We then assume that environmental factors,

which are not directly accounted for, shall contribute to the degradation of
 200 molecular species with respective degradation rates of $\bar{\delta}_m$. Dynamics for the
 molecular species are then collectively written as

$$\frac{\partial \bar{m}}{\partial t} = \nabla_x \cdot \text{diag}(\bar{D}_m) \nabla_x \bar{m} + \int_{\mathcal{P}} \bar{\Phi}_m(y, \bar{m}, c, v) dy - \text{diag}(\bar{\delta}_m) \bar{m}. \quad (9)$$

Finally, spatial dynamics for the drug species vector, $\bar{p}(t, x)$, are also given
 by diffusive dynamics, with a rate vector $\bar{D}_p$. We then represent the input
 205 of drug species to the population as a vectorial function, $\bar{\theta}(t, x)$, which is to
 define the drug regimen used by the clinician/scientist in treating the tumour.
 This will normally be given by a sum of Dirac delta functions centred at the
 time of injection of the drug but may be given by other forms and will be
 particular to the experiment that the model attempts to replicate. Finally,
 210 we assume that the drug's effect on the cellular system requires the drug to be
 taken in by cells and systematically degraded during apoptosis. Therefore, given
 a drug degradation vector, $\bar{\delta}_p$, this degradation shall be committed by the non-
 structured cellular population, written as the integral $\int_{\mathcal{P}} c dy$. The complete
 equation for drug dynamics is then given by

$$\frac{\partial \bar{p}}{\partial t} = \nabla_x \cdot \text{diag}(\bar{D}_p) \nabla_x \bar{p} + \bar{\theta}(t, x) - \text{diag}(\bar{\delta}_p) \bar{p} \int_{\mathcal{P}} c dy. \quad (10)$$

215

2.5. Summary of the General Mathematical Model

We then write the system of PDEs as

$$\left\{ \begin{aligned}
 \frac{\partial c}{\partial t} &= \underbrace{\nabla_x \cdot [D_c \nabla_x c + c(1 - \rho(c, v)) (\nabla_x (\bar{\chi}_m \cdot \bar{m}) + \nabla_x \chi_v v)]}_{\text{Spatial Flux}} \\
 &\quad + \underbrace{\nabla_y \cdot \Sigma(y, \bar{m}, \bar{p}) \nabla_y c - r_\mu \nabla_y \cdot \Psi(y, \bar{m}, \bar{p}) c}_{\text{Structural Flux}} + \underbrace{\Phi_c(y, \bar{m}, c, v) c}_{\text{Growth}} - \underbrace{\delta_c \bar{f}(y) \cdot \bar{p} c}_{\text{Drug Influence}} \\
 \frac{\partial v}{\partial t} &= \underbrace{\Phi_v(c, v) v}_{\text{ECNE Remodelling}} - \underbrace{\bar{\delta}_v \cdot \bar{m} v}_{\text{MMP Degradation}} \\
 \frac{\partial \bar{m}}{\partial t} &= \underbrace{\nabla_x \cdot \text{diag}(\bar{D}_m) \nabla_x \bar{m}}_{\text{Spatial Diffusion}} + \underbrace{\int_{\mathcal{P}} \bar{\Phi}_m(y, \bar{m}, c, v) dy}_{\text{Chemical Synthesis}} - \underbrace{\text{diag}(\bar{\delta}_m) \bar{m}}_{\text{Natural Degradation}} \\
 \frac{\partial \bar{p}}{\partial t} &= \underbrace{\nabla_x \cdot \text{diag}(\bar{D}_p) \nabla_x \bar{p}}_{\text{Spatial Diffusion}} + \underbrace{\bar{\theta}(t, x)}_{\text{Drug Input}} - \underbrace{\text{diag}(\bar{\delta}_p) \bar{p} \int_{\mathcal{P}} c dy}_{\text{Drug Degradation}} .
 \end{aligned} \right. \tag{11}$$

This system of equations (11) is considered together with no-flux boundary conditions in c , m , and $\bar{p}$. In the case of c we consider zero spatial fluxes, and zero structural fluxes on the boundaries of the spatial and structural domains, respectively.

In the following sections, we present an intuitive explanation for the origin of the equations and relations used for two particularisations of this general mathematical system, along with a thorough description of the biological evidence for such phenomena.

3. Mutational Evolution and the Establishment of Drug Resistance

3.1. Resistance to BRAF inhibitors (BRAFi) and antibody therapies in melanoma

Melanoma is one of the most common cancers of the skin and approximately 50% of melanomas contain a mutation in an oncogene known as BRAF, often appearing at codon 600 [14]. Therefore, BRAF inhibitors (BRAFi) have been the major drug of choice in treating advanced melanoma tumours and their

235 various subtypes. The application of BRAFi as an anti-oncogenic, however, has
had mixed results due to the frequent presence of BRAFi resistant phenotypes
existing as subspecies within the overall melanoma species [15, 16, 17, 18, 19].
The resistance mechanism could involve activation of collateral signaling path-
ways when the main signaling is inhibited [20]. For this reason, simultaneous
240 inhibition of several pathways is often proposed as a possible strategy against
resistance [20].

Moreover, recent studies suggest that intravenously injected, water-soluble
MAPK activator can overcome, to some extent, the resistance to BRAFi [21].
This, in turn, suggests that the penetration to the inner domain of the tumour
245 is a critical component of the destruction of the resistant cancer cells. More-
over, BRAFi is often used in combination with MEKi in order to target several
mechanisms of activation within the MAPK pathway.

In animal models, as well as in patients, relapse occurs systematically sev-
eral months after treatment with BRAFi [22]. Studies have shown that the
250 adaptations and resistance to BRAFi happen early in the treatment process
[23, 24], which may suggest that cancer cells have acquired a resistant state
before application of BRAFi.

The order in which drugs are supplied to the tumour may also have a signif-
icant effect on the clinical outcome. Progression-free survival rates were higher
255 among those receiving immunotherapy prior to BRAFi than vice versa [25]
whereas one particular study looking at treatment with immunotherapy and
BRAFi found that preceding BRAFi with immunotherapy does not alter the ef-
fectiveness of the drug. Treatment with immunotherapy post-BRAFi, however,
gives the patient a particularly poor clinical outcome [26].

260 One strategy for drug application on the premature tumour has been shown
to apparently forestall the resistance to BRAFi. This methodology involved
applying the drug to the tumour, for a period of time appearing to demonstrate
a reduction in the tumour volume, before removing the drug and repeating
the process, again. This method showed mixed results although a significant
265 number of the resistant tumours did not survive the treatment [27].

Tumours that have been shown to have innate BRAFⁱ resistance have further been shown to have increased incidence of mutations in genes known as NRAS [28, 29] and PTEN [30], respectively.

In human liver cells, those cells with an induced PTEN knockdown have been
270 shown to increase the rates of Akt phosphorylation and, importantly, to inhibit
Foxo1 signalling [31]. Foxo1, in return, is a transcription factor responsible for
mediating the T-cell response to healthy cells [32]. In CD8⁺ T-cells, Foxo1 has
been shown to have an intrinsic role in establishing long-lived memory programs
that are essential for developing cells capable of immune reactivation during
275 secondary responses to infection [33, 34].

On the other hand, the gene encoding for phosphatidylinositol 3-kinase
(PI3K), whose oncogenic pathway is inhibited by PTEN expression, has been
shown to reduce the cytokine expression in cells [35], thereby reducing the in-
flammatory response of the surrounding tissue and limiting T-cell recruitment to
280 the site. Cells with a PTEN deletion might then be protected from immune re-
sponse through mediation of cytokines and the local apoptosis induced through
PI3K/Akt signalling, which may subsequently be overcome by the induction
of T-cell hyperactivity induced by ipilimumab – a melanoma-specific immune
enhancer therapy.

285 Therefore, it is possible that melanoma cells undergo sequential genetic al-
terations in BRAF and PTEN, respectively, and that the pattern in which these
mutations occur, along with considerations with respect to competition for nu-
trients, could explain the build up of resistance to the combined effects of BRAFⁱ
and ipilimumab anti-oncogenic treatments.

290 It may also be that BRAF mutated cells, as a result of causal genomic insta-
bility, acquire NRAS mutations which confer resistance. This change, for exam-
ple, was observed within ovarian cell lines and was predicted to have formed as
a result of exon 11 BRAF mutations being insufficient to satisfactorily activate
the MAPK pathway, requiring additional NRAS activity [36]. Furthermore,
295 BRAF V600E cells have sufficient MAPK activity such that they do not neces-
sitate supplementary mutation and, as such, display a more positive response

to therapy [37], which is supported in the majority of cases of melanoma with a native BRAF mutation [38]. Yet, despite the fact that BRAF and NRAS mutations are described commonly as “mutually exclusive”, NRAS mutations appear in increased numbers of BRAFi resistant tumours [29].

In our model, we interpret the primary and consequent mutation to be that in BRAF and assume, further, that the cell will acquire some further mutation capable of conferring resistance to BRAF inhibitors.

3.2. Interpreting the structural dimension for a mutational system

In order to understand how this system of sequential mutations contributes to the cancer cell population’s success at avoiding targeted and immune-enhancement therapies, we must first interpret the structural-, y -, dimension. So, letting the cellular population be given by a function $c(t, x, y)$ and the ECNE concentrations be given by the function $v(t, x)$, with $\bar{m}(t, x)$ and $\bar{p}(t, x)$ giving the molecular and drug species, respectively, we observe the bio-mathematical dynamics of such a system in the structure space, $\mathcal{P}$.

We also assume, that the cellular species will migrate unidirectionally through the structure space, which is to say that mutations are irreversible. Let the structural mutation variable and space, then, be given by the interval $y \in \mathcal{P} = [0, 1]$, such that $y = 0$ and $y = 1$ give the extreme states of primary tumour (or as yet without a mutation) and resistant, respectively. For ease, let us also define that $y = 1/2$ defines a BRAF mutation and the state at which the cellular species is most sensitive to BRAFi. Realistically, the ipilimumab immune-enhancer drug will be effective across the entire spectrum of mutations but we assume it to be most effective posterior to BRAF mutation and prior to complete consolidation of resistant features at $y = 1$.

3.3. Growth, ECNE remodeling and drug dosing in a mutational system

Let $\rho(t, x)$ be defined as in 2 such that the growth of the cellular species, $c(t, x, y)$, shall be dependent upon the unoccupied local volume, $1 - \rho(t, x)$ and

is also dependent upon the nutritional species, $m_2(t, x)$, being above a given threshold, θ_{m_2} . The cellular growth rate, with an overall rate parameter ϕ_c , is then written as

$$\Phi_c(y, \bar{m}, c, v) = \phi_c(m_2 - \theta_{m_2})(1 - \rho(c, v)), \quad (12)$$

330 where we consider that growth, in this case, is not dependent upon the mutational status of the cells y .

Again, the ECNE remodelling takes place within the unoccupied portion of the local available volume, $1 - \rho(t, x)$, and with a rate constant ϕ_v , such that

$$\Phi_v(c, v) = \phi_v(1 - \rho(c, v)). \quad (13)$$

Although we assume here that ECNE remodelling is only dependent on the unoccupied volume, we recognise that more realistically this could depend on 335 fibroblast cells and ultimately on the cell phenotype represented by y . Therefore, future iterations of this modelling approach could incorporate more complex remodelling through a redefinition of the Φ_v term.

We then endow the system with two molecular species. m_1 is a species that 340 is secreted by the cell species and will act to degrade the ECNE. This can be thought of as a matrix metalloproteinase (MMP) which acts to break-down the ECNE. m_2 is a species which is secreted by the ECNE and acts to the benefit of the cellular species. This chemical species can be thought of as a nutrient or growth factor, the presence of which aids the growth of cellular species.

345 We further assume that more mutated and aggressive cellular populations will produce MMP molecules at a greater rate, such that their production is proportional to y , and that the overall rate constant is given by ϕ_{m_1} . We write this as

$$\Phi_{m_1}(y, \bar{m}, c, v) = \phi_{m_1}(1 - m_1)yc. \quad (14)$$

Nutrient, or nutritional species, are produced by the ECNE and with a rate of 350 ϕ_{m_2} , such that

$$\Phi_{m_2}(y, \bar{m}, c, v) = \phi_{m_2}(1 - m_2)v. \quad (15)$$

We assume an instantaneous introduction of drug species through the vasculature, which we assume to be proportional to ECNE concentration. The instantaneous nature of this drug introduction mean that we may write this as a Dirac delta function $\check{\delta}(t - \tau)$ centered at some time τ , whilst its introduction through the vasculature of the ECNE is represented by proportionality to $v(t, x)$. Then, given that the number of doses of some j^{th} drug species, $p_j(t, x)$, is a natural number, $N_{p_j} \in \mathbb{N}$, we write that the doses are given at the ordered set of time points $\{\tau_{j,1}, \tau_{j,2}, \dots, \tau_{j,N_{p_j}}\}$, $\tau_{j,1} < \tau_{j,2} < \dots < \tau_{j,N_{p_j}}$. Then the mathematical expression for drug dosing is given by

$$\theta_j(t) = v(t, x) \sum_{k=1}^{N_{p_j}} \check{\delta}(t - \tau_{j,k}). \quad (16)$$

3.4. Mutational dynamics in melanoma: Phyletic gradualism or punctuated equilibria?

Patterns in genetic evolution can generally be categorised by the theory of punctuated equilibrium (PE) or phyletic gradualism (PG). PG originates in the theory of Darwinian evolution by natural selection and seeks to explain the variety of species by continuous gradual change [39, 40]. PE, on the other hand, is a currently prominent theory in evolutionary biology that seeks to explain the nature of evolution by natural selection through the prism of large scale genetic and environmental changes, rather than a gradual process [41, 7]. Recent papers in the field of evolutionary biology advance the PE framework as a superior explanation of microbiological, paleontological, and phylogenetic evidence available today [42].

Starting with pioneering contributions of Knudson [43], Cairns [44] and Nowell [45], theory of evolution and population genetics ideas were applied to explain cancer progression. These theories added chromosome instabilities and selection processes to the older idea that cancer results from an accumulation of somatic mutations [46]. Furthermore, the gradual accumulation of mutations over time has been challenged by recent evidence that tumours evolve by

380 a few catastrophic events that generate large scale genome[47] or chromosome
 lesions[48, 49]. These findings suggest that cancer genomes evolve by PE, being
 thus able to acquire quickly new capacities such as invasiveness and drug resis-
 tance [50, 51, 52]. This PE can be explained on a more microscopic level by
 assuming that the intermediary stages of mutation, although significant, happen
 385 more quickly and to greater effect under certain optimal conditions. Conflict-
 ingly, gradualism would convey a sense of regular and linear progression within
 the phyletic tree of the cancer species with little or no change in the rate of
 mutation.

Single-cell genetic analysis reveals clonal frequencies and phylogeny patterns
 390 of evolving tumours [53, 54, 55, 56]. Various clones have heterogeneous survival
 properties in the presence of drugs; as a result of this selection pressure, drug
 resistant clones can become predominant. For instance, mutations of the genes
 BRAF and NRAS are well known to be driver mutations for melanoma [57,
 58, 59, 60]. The wealth of literature on melanomal branching evolution has
 395 identified BRAF as the major trunk driver mutation and NRAS or MEK1 as
 the major branch driver mutations [61, 62]. It has also been recognised that
 the targeted treatment of genetically evolved melanoma results in a reduction
 of their heterogeneity [59], as only drug resistant genetic variants survive, but
 not in their eradication.

400 For the sake of simplicity, in our model we consider that only two mutations
 can occur, and that their occurrence is sequential.

3.5. *A structural flux function in a mutational system*

To clarify the mathematical evolution of our cancer cell population, we
 405 must more clearly define how the population changes in structure, through
 the normalized structural velocity $\Psi(y, \bar{m}, \bar{p})$ (further discussion in Appendix
 A.1). This function is intended to represent the velocity of any given cell in
 the y -direction (in other words, the mutation rate), for given current structural
 state (y -coordinate) and local nutritional condition, $m_2(t, x)$. We shall define a
 410 separate normalized structural velocity for both a PG and a PE assumption.

Figure 2: Normalized structural velocity, $\Psi(y, \bar{m}, \bar{p})$ for the (a) phyletic gradualism (PG) and (b) punctuated equilibrium (PE) assumptions.

In the case of PG, we wish for the evolution of this population to be steady and regular throughout the domain, such that the mutation rate must fundamentally be constant throughout the domain. Then, in order to ensure that our population does not migrate beyond the boundaries of the domain, $y = 0$ or $y = 1$, we set the values of the normalized structural velocity to 0 at these locations, yielding no mutation at these biological positions (Fig. 2a).

In the PE case, we require for the mutation rate to be significantly greater in periods between mutational realisation than at those positions themselves. Therefore, we represent the normalized structural velocity as a bimodal function with velocity maxima positioned between the mutational states. Likewise with the PG function, however, we require for the PE paradigm to yield a 0, non-mutational behaviour at the boundaries of the domain (Fig. 2b). Remember, given that these function represent the rate of mutation, a higher value of $\Psi(y, \bar{m}, \bar{p})$ will convey a faster rate of mutation whilst a lower value will convey a more quiescent state, where change is somewhat slower.

For the sake of simplicity, we do not consider genetic diversification and structural diffusion in this context.

3.6. Drug effectiveness functions in a mutational system

The drug effectiveness is given by a vector valued function $\bar{f}(y) := [f_1(y), f_2(y)]^T$,

Figure 3: Distribution for the drug effectiveness functions $f_1(y)$ (*green*) and $f_2(y)$ (*red*).

where $f_i(y)$ gives the effectiveness of its corresponding i^{th} drug, $p_i(t, x)$. For simplicity, we assume that each of these functions is given by a Gaussian function centred at its point of greatest structural significance, or the structural location in y at which it is most effective against cancer cells.

Now, since $p_1(t, x)$ is define to be a BRAFi therapy and we have defined
that the BRAF mutation is fully realised at the structural location $y = 1/2$, we
assume that $f_1(y)$ attains its maximal value at $y = 1/2$ (Fig. 3 *green*). The
considerations for ipilimumab are somewhat more numerous and difficult to
entirely confirm but are, for our purposes, limited to the following. Firstly, we
assume that immune cells should largely ignore healthy cells without a mutation
such that there effectiveness at $y = 0$ should be negligible. Moreover, we know
that cancer cells will eventually become resistant even to this immune-enhancer
therapy and, as such, the value of effectiveness function must be sufficiently
low in the neighbourhood of $y = 1$, so as to allow this resistance phenomenon
to manifest. Likewise, immune cells require the expression of some protein on
the surface of any given cell in order to identify its genetic properties; as such,
we assume that only as the BRAF mutation becomes realised, near $y = 1/2$,
shall the ipilimumab therapy begin to have a significant effect. Given these
considerations, we place the maximum of f_2 at $y = 3/4$ (Fig. 3 *red*).

4. Results for the Mutational System

Primarily, in the application of this system to studying the death and re-growth models of tumour resistance in mice, we wished to know whether or not

our *in silico* model was able to recapitulate *in vivo* results. In the process of exploring this potential in the model, we attempt to asses the ability of either
455 phyletic gradualistic or punctuated equilibrium assumptions, on the tumour’s evolution, were more able to consistently capture this phenomenon (Section 4.1). Secondly, we wished to test whether, given knowledge of sequenced treatments’ ability to succeed in the ablation of the tumour, we could draw conclusions about the sequencing of treatments and their relative success (Section 4.2). In
460 line with this, we tested periodic treatments to understand what the heterogeneity in initial conditions of the tumour could teach us about the outcomes for treatments (Section 4.3) and, finally, what effect a heterogeneous environment would have on these above conclusions (Section 4.4); whether results would be conserved or altered in the presence of a heterogeneous spatial conditions.

465 In order to test these scenarios, the *in silico* experimental approach was primarily as so: We began by choosing a melanoma mouse model for which one could attempt to tune our parameters and, effectively, challenge the model. The model that we chose for this task was that of Perna *et al.* who explored the explosive regrowth of tumours after some post-treatment dormancy period
470 [22], amongst other things. Once we had used this *in vivo* model to tune and test our mathematical *in silico* model, we would use other biological models in order to challenge the mathematical model with no further doctoring of the mathematical model or its parameters. For this challenge we chose, initially, that of Thakur *et al.* [27].

475 Thus, we obtain that these mutations occur at maximal probabilistic rates of approximately 1.9×10^{-2} genetic events per day. This corresponds to acquiring a genetic mutation every 40-50 days posterior to some precursor event, where we consider only 2 such events. This is supported by the fact that tumours planted in the mouse species show significant change in expression pattern after 25-45
480 days [63, 64], where below 40 days BRAFi was a largely successful treatment [65], and mouse models show significant behavioural change in the cancer cell dynamics after 100 days since inoculation [22].

Proliferative and degradative parameters were chosen to be in line with pre-

Figure 4: **Punctuated evolution is more consistent with biological results than gradual evolution.** Tumour volume graphs for (a) punctuated equilibrium (PE) and (b) phyletic gradualism (PG) assumptions under a simply BRAFi therapy option applied at $t = 40$ for initial conditions of $\eta = 0.05$ or $\eta = 0.05 + r$, where η represents the initial mean location of the tumour cells along the phenotypic dimension, and $r = 0.1$ represents a perturbation.

vious models and were fine-tuned for the mouse model considered, based on
485 tumour growth rates observed in tuning experiments [22]. All of these values
are summarised in Table B.1.

4.1. *Punctuated equilibrium (PE) assumptions are more consistent with in vivo experimental results than phyletic gradualism (PG) assumptions*

490 Given certain initial conditions for the cellular population, namely an initial structural distribution centred at $\eta = 1/20$, both PE and PG assumptions can give rise to the characteristic death and regrowth curves, albeit with differing characteristics (Fig. 4). In both cases, one observes an initial growth phase

which is quickly stunted and violently reversed by the introduction of the drug
 495 species at $t = 45$. This is followed by a period of dormancy or ‘tolerance’ before
 the characteristic resistant growth (or regrowth) phase, which is of particular
 interest to our current study. Observe, initially that the regrowth phase mani-
 fests a an earlier time point and with a faster growth rate under PE assumptions
 than with PG assumptions.

500 Now, observe that inducing a significant (200%) perturbation in only the
 position of the initial conditions, we evoke dramatically differing behaviours
 from our two *in silico* tumours (Fig. 4). For the case of PE, the rate at which
 our tumour regrows to its pre-treatment volume is much slower but the death
 and prolonged dormancy phases are conserved between these two experiments
 505 (Fig. 4a). Under the assumptions of PG, however, one observes at all time
 points a tumour volume with a significant positive minimum value (Fig. 4b).
 This shift in the volumes of tolerant tumours to be visible for all time points
 is not consistent with the results of comparative *in vivo* experiments [22] and,
 thusly, the initial conditions of a PG model would have to be strictly constrained
 510 to some smaller subset of possible conditions in order to maintain its relevance.

In biological, and especially in the case of *in vivo*, experimentation, however,
 the initial conditions of a given tumour or its new environment may never be
 strictly limited. This would suggest, due to its robustness to fluctuations in
 initial conditions, that the PE modelling assumption is most consistent with the
 515 results of murine experimentation, since the characteristic death and regrowth
 curve is conserved.

4.2. Sequencing and order of treatments are vital to their success

In order to test the importance of the order of drug treatments on the re-
 520 sistance phenomenon we have first used homogeneous initial conditions for the
 ECNE. These conditions also preserves the spherical symmetry of the tumour
 when drugs are applied uniformly on the periphery. Heterogeneous initial condi-
 tions leading to non-spherically symmetric tumours will be tested in Section 4.4.

Figure 5: **The sequencing of treatments is crucial to success.** Overall tumour volume over time, calculated using (B.5), with the drug strategies (a) BRAFi, (b) ipilimumab, (c) BRAFi followed by ipilimumab, and (d) ipilimumab followed by BRAFi; where the drugs are applied constantly after some $t = 45$ (1^{st} green arrow) and then $t = 100$ (2^{nd} green arrow) when applicable

With that understood, in all cases and treatment scenarios the tumours initially respond to treatment, exhibiting a significant period of apoptotic degradation (Fig. 5). Experiments wherein only one treatment was used (Fig. 5a & 5b) show dramatically differing clinical treatment profiles. BRAFi treatment shows an extremely promising tumour response with almost complete eradication occurring within days of treatment but followed by an exaggerated regrowth (Fig. 5a), as seen in murine experiments. Ipilimumab therapy does not show as successful an eradication pattern at earlier time points but is more consistent in quelling its resistance and resulting regrowth (Fig. 5b), although ultimately unsuccessful in eradicating the tumour.

Observing the therapeutic strategy of utilising a BRAFi treatment followed

535 by an ipilimumab post-treatment is ineffective at destroying the tumour (Fig.
 5d). Although the ipilimumab post-treatment is slowing the growth of the now
 aggressive tumour, it may already be resistant to immunological therapies. The
 ipilimumab treatment followed by BRAFi post-treatment, however, appears to
 be extremely effective (Fig. 5d), with a negative growth rate for the tumour vol-
 540 ume maintained as of $t = 1000$ (Results not shown). This counterintuitive result
 may be explained as follows: Firstly, BRAFi appears extremely effective at de-
 pleting the tumour volume but is incapable of preventing the resistant escape of
 subpopulations to higher values of y (Fig. 5a). On the other hand, ipilimumab's
 effectiveness function is centred at a greater value of y than BRAFi's, making
 545 ipilimumab appear less effective but allowing ipilimumab to effectively confine
 surviving tumour cells at lower values of y , where BRAFi remains effective.
 Therefore, these results would suggest that BRAFi should be used to destroy
 the tumour once its tendency towards resistance has been stemmed through
 ipilimumab's immunological mechanisms.

550

4.3. *Oscillatory tumour volumes as a result of periodic treatments do not nec- essarily imply re-sensitisation*

Our second experimental approach was to attempt the experiment of Thakur
et al. [27] who implemented a periodic treatment regimen for their *in vivo*
 555 tumours. This periodic treatments managed to eradicate the death and rapid
 regrowth phases of those previous experiments and instead resulted in oscillatory
 dynamics in the tumour volume. Across several cycles of these treatments, some
 tumours managed to outgrow the drugs and became resistant, although more
 slowly, whilst others appeared to reduce their volume even over far longer time-
 560 periods. The research team explained this by suggesting that the application
 of less severe treatment regimes may delay the resistance to treatment in solid
 tumours by failing to encourage the development of such resistance.

Likewise, in our experiments we observed an oscillatory dynamics resulting
 from the periodic application of smaller dosages to the tumour and subsequent
 565 removal of the dose. We found that as we increased the number of independent

Figure 6: **Oscillatory tumour volumes can emerge in the absence of re-sensitisation.** The *top* and *middle* panels are figures from Das Thakur *et al.* [27] for *in vivo* melanoma tumours under an intermittent dosing strategy and the *bottom* panel gives the *in silico* results of the same experiments run using the mutational mathematical model. (Licenses applied for from Nature Publishing Ltd.)

starting y positions in the initial conditions for our cancer cell population, our results gave a greater qualitative agreement with those of Thakur *et al.* [27]. Moreover, we found that there was a strong correlation between the average y -position of the initial condition and the final tumour volume at $t = 160$.

570 These results allowed us to reinterpret this oscillatory behaviour. In our *in silico* model, the acquisition of resistance is certainly not delayed because cells are progressing irreversibly in the y direction. In fact, what may be occurring is that in a situation where some number of cells are resistant whilst other are not, these two heterogeneous subpopulations will have to compete for available
575 nutrients in the environment. Not only this but, together, they will consume

Figure 7: **Spatial heterogeneity eradicates treatment success.** Panels displaying (*top*) the structured cellular population with space across the lower plane and mutational state given along the vertical axis; (*middle*) the spatial cellular distribution; and (*bottom*) the ECNE density, where ipilimumab treatment is given at $t = 40$ and BRAFi treatment is given at $t = 100$, for time points $t \in \{5, 40, 80, 120\}$ are shown.

more nutrients, leaving fewer such nutrients for the resistant subpopulation and leaving a greater subpopulation sensitive to existing treatment options. A dynamical state will be reached where the two sub-populations are oscillating while keeping their volumes bounded.

580

4.4. Drug success rates decay under heterogeneous spatio-environmental assumptions

In order to examine the effect that spatial heterogeneity of the ECNE concentrations and, thusly, the resulting cancer cell population on the longer term effectiveness of targeted and immunological treatments, we considered only that treatment protocol which proved effective in the homogeneous case; namely that of an ipilimumab treatment followed by BRAFi post-treatment. The introduction of spatial heterogeneity whilst maintaining all other factors, in their en-

585

Figure 8: **Spatial heterogeneity eradicates treatment success.** Panels displaying (*top*) the structured cellular population with space across the lower plane and mutational state given along the vertical axis; (*middle*) the spatial cellular distribution; and (*bottom*) the ECNE density, where ipilimumab treatment is given at $t = 40$ and BRAFi treatment is given at $t = 100$, for time points $t \in \{160, 200, 240, 280\}$ are shown.

tirety, was sufficient to cause the degeneration of treatment success into the
 590 characteristic death and regrowth curves seen previously (Results not shown,
 although they may be inferred from figures 7 & 8 *middle*).

Notice, firstly, that the spatial cancer cell population (Fig. 7 & 8 *middle*)
 initially spreads to the nearby regions of elevated ECNE concentration, prior
 to treatment. As the treatment is applied, and the regions of highest cell pop-
 595 ulation coincide with the regions of highest ipilimumab concentration, the cell
 population is reduced to invisibility for some times $40 < t < 200$. It should be
 understood, here, that under a great evolutionary selective pressure only very
 few cells survive these initial waves of treatment but those cells which do survive
 will be completely resistant to both treatments. At this time, and with almost
 600 the entirety of the surviving cellular population being resistant to both BRAFi
 and ipilimumab, the cellular population begins to regrow at regions of highest

nutritional content, or ECNE.

One may observe this dynamic in the spatio-structural cellular population, progressively over the entire time domain. Consistently with the punctuated
605 equilibrium assumptions within the model, one notices a pulsatile movement of the cellular subpopulations between $y = 0$ and $y = 1/2$, and again towards $y = 1$ (Fig. 7 & 8 *top*). In particular, however, the first time at which the cancer cell population has been visibly eradicated (Fig. 7c), the visible coincidence of those areas of low ECNE concentration with those cancer cell clusters at the
610 most elevated value of y . In other words, the difference in the heterogeneous case, as compared with the homogeneous case, is that the cancer cell population is able to preferentially avoid drug-induced apoptosis by remaining in regions of low ECNE and drug concentrations, which allows the cellular population to become resistant before migrating to regions of high nutrition and increasing
615 their collective proliferation rate.

This demonstrates that particular prudence must be paid during consideration of spatial factors in the study of drug resistance and strategy. One should also notice the clinically difficult tumour that results from this method of treatment (Fig. 8d *middle*) and the nature of the underlying environmental
620 infrastructure, or ECNE. The tumour is viable although sparsely populated which raises significant questions about the ability to remove such a tumour, surgically. The approach to treating such a patient would classically be to use chemical means, which have now been exhausted and given rise to a uniformly resistant tumour.

625

5. Metabolic Remodeling and the Re-Establishment of Drug Sensitivity

Recent studies have looked at the effect of BRAFi on the human melanoma PDX lines implanted in the immunodeficient mouse and found that this drug is
630 largely ineffective, implicating a role for the immune system in its functioning. This result is contrasted with the effectiveness at eradicating the tumour with

BRAFi+MEKi, again with the characteristic relapse curve [66].

These same studies have suggested that after a primary phase of treatment, and subsequent washing of the drug species from the tumour, the cancerous cells may regain their sensitivity [66]. This is illustrated in the cells' recapitulation to later phases of treatment and suggests that some metabolic, or other, plasticity may lead to the observed resistance to BRAFi and MEKi. This plastic response may be reversed upon the removal of the drug and is believed to be as a direct result of stress on the cells themselves.

Beyond these conclusions of the study, the observation is made that the system remains the genetic equal of the precursor tumour at every stage during this adaptive process. This suggests that a population-wise phenotypic switch occurs from populations that are composed 1% of epigenetically resistant cells, prior to treatment, to being comprised 70% of this cell type, post-treatment and post relapse [66]. Little is known about the phenotypic status of the tumour immediately prior to the secondary round of BRAFi+MEKi dosing.

Moreover, cutaneous tissue is naturally and significantly heterogeneous in its composition and, being the tissue furthest from the major vasculature, is greatly dependent on the arterial supply of oxygen and other nutritional components of the cellular system. In areas with the lowest such supplies of oxygen, cells switch their metabolism from mostly oxidative phosphorylation (oxphos) to glycolysis. Using, then, BRAFi and MEKi in order to inhibit the glycolytic pathway [67, 68] induces an excessive stress regimen within the cell. It has been suggested that, under such powerful metabolic stresses, the cell will diversify its metabolic behaviour in order to attempt an increase in efficiency. This switching between glycolytic and oxphos modes of metabolism may, therefore, be instrumental in facilitating the avoidance of targeted inhibition within cancer cells; cancer cells may use oxphos metabolism to avoid the targeted inhibition of glycolysis [69].

This, however, implies that we are now existing within a different paradigm with respect to the evolution of the cells in response to drug application or, perhaps, in general. To begin with, we recall that $p_1(t, x)$ is given by the spatio-temporal concentration of BRAFi and we, now, redefine that $p_2(t, x)$ should

Figure 9: Visual reinterpretation of the structural y variable to account for the metabolism of glucose molecules proportionally and competitively through glycolytic and oxphos pathways, respectively.

be given by the spatio-temporal concentration of MEKi, a second metabolic inhibitor of glycolysis.

665

5.1. Re-interpreting the structural dimension for a metabolic system

In order to capture the re-sensitisation phenomenon, we must reinterpret the structural y variable to take into account the newfound plasticity of the cellular population. We assume that the effect of the drugs and the variability in the cellular population may be adequately illustrated through the cellular pathways involved in the metabolism of glucose; namely those of glycolysis and of oxphos. Given that a given glucose molecule, may be metabolised through the utilisation of either one of these pathways, but not both, we may represent the structure of the cell as the proportion of glucose sent to glycolytic pathways as opposed to oxphos pathways; such that $y = 0$ represents 100% of glucose being metabolised through glycolysis, and 0% by oxphos, whilst $y = 1$ represents 0% of glucose being metabolised through glycolysis, and 100% by oxphos (Fig. 9).

675

5.2. A cellular growth function in a metabolic system

Likewise with our previous paradigm, we assume that proliferation requires the presence of nutrients, $m_2(t, x)$, above a certain threshold, θ_{m_2} . As was recognised by Warburg in 1956 [70], and was subsequently termed the Warburg effect, highly proliferative cancer cells appear to preferentially utilise glycolytic pathways to synthesise membrane lipids and other essential components from

680

685 glucose. Therefore, we assume that there exists some underlying proliferation
rate, $\phi_{c,1}$, which is common amongst all cells and a further ‘Warburg’ prolifer-
ation rate, $\phi_{c,2}$, which is contributed dependent upon the degree to which the
cell utilises glycolysis; as the cell utilises the glycolytic pathways to a greater
extent, its proliferation rate shall increase concurrently. Moreover, since we are
690 particularly interested in the cell’s ability to absorb and utilise available nutri-
ents in the environment, we modify our competition assumptions so that the
cellular population’s proliferation will not be inhibited by the presence of the
ECNE but will rather simply increase the pressure on the ECNE itself. Thusly,
we replace the unoccupied volume term by $1 - \int_{\mathcal{P}} c \, dy$ and write the full growth
695 term as

$$\phi_M(y, c, \bar{m}) := c \left(1 - \int_{\mathcal{P}} c \, dy \right) \left(m_2 - \theta_{m_2} \right) \left(\phi_{c,1} + \phi_{c,2}(1 - y) \right). \quad (17)$$

5.3. A structural flux function in a metabolic system

The cell is biologically engineered to complete its cell cycle and evolution
has selected for cellular populations who are particularly efficient at achieving
700 this goal. Therefore, given that a cell requires nutrition and the ability to freely
adapt in order to achieve this objective, if the cell is deprived of its essential en-
vironment then it will take extreme measures in order to continue to proliferate.
We here define stress, or ‘stressed conditions’, as those conditions which are not
conducive to cellular metabolism and proliferation. In particular, those scenar-
705 ios which would lead the cell to feel ‘stressed’ are given explicitly by nutritional
deprivation or targeted inhibition of metabolically essential genes, such as BRAF
or MEK. Therefore, we define the weighted stress term as $\psi_{p_1} p_1 + \psi_{p_2} p_2 - \psi_{m_2} m_2$,
where ψ_{p_1} , ψ_{p_2} , ψ_{m_2} , are positive weights such that $\psi_{p_1} + \psi_{p_2} + \psi_{m_2} = 1$. Un-
der stress, the cell shall randomly diversify its behaviour; each cell becoming
710 stochastically more or less oriented towards glycolytic metabolism such that the
population, as a whole, becomes more metabolically diverse. Therefore, we may
represent this at the population level by a structurally diffusive behaviour. The

Figure 10: Distributions for the drug effectiveness functions $f_1(y)$ (green) and $f_2(y)$ (red).

structural diffusion coefficient $\Sigma(y, \bar{m}, \bar{p})$ is proportional to the weighted stress, therefore

$$\Sigma(y, \bar{m}, \bar{p}) = \sigma_c (\psi_{p_1} p_1 + \psi_{p_2} p_2 - \psi_{m_2} m_2) , \quad (18)$$

715 where σ_c is a positive constant. In the absence of stress, the cell population relaxes by advection to the preferential metabolic state $y = \omega_c$. The relaxation rate is proportional to the weighed non-stressed factor defined as $1 - \psi_{p_1} p_1 - \psi_{p_2} p_2$. Thus, the normalized structural velocity reads

$$\Psi_M(y, \bar{m}, \bar{p}) = \bar{\sigma}_c (\omega_c - y) (1 - \psi_{p_1} p_1 - \psi_{p_2} p_2) , \quad (19)$$

where $\bar{\sigma}_c$ is a positive constant.

720

5.4. Drug effectiveness functions in a metabolic system

The drug effectiveness functions for BRAFi and MEKi, $p_1(t, x)$ and $p_2(t, x)$ respectively (further discussion in Appendix A.2), are given simply by Gaussian functions centred at $\alpha_{f_1} = 0$ and $\alpha_{f_2} = 3/10$ respectively. We write these

725

mathematically

$$\begin{cases} f_1(y) := \exp[-\beta_{f_1}(y - \alpha_{f_1})^2] \\ f_2(y) := \exp[-\beta_{f_2}(y - \alpha_{f_2})^2] . \end{cases} \quad (20)$$

whilst the widths of these Gaussian functions are uniform with $\beta_{f_1} = \beta_{f_2} = 50$

(Fig. 10), in order to replicate results from the murine models from [66].

6. Results for the Metabolic System

Again, our primary motivating factor for these metabolically plastic systems
730 was to understand whether these mathematical models were capable of recreat-
ing or predicting the complex dynamics underlying *in vivo* results (Section 6.1).
Beyond this, we wished to try to understand the spatio-metabolic dynamics of
the tumour which are allowing resistance to develop (Section 6.2). Finally, given
the complexity of the plastic model, we wished to know what the dynamics of
735 the cellular population, under the influence of drugs, might tell us about the
reaction of this population to treatments and the clinical significance of this
reaction (Section 6.3).

In order to test this *in silico* model, we attempted to recreate the conditions
in the experiments run by Rambow *et al.* [66]. In these experiments, mice were
740 given a PDX melanoma and the tumour was allowed to grow for some initial
period without treatment. Tumours were then treated with BRAFi+MEKi
combination therapy at a time point which corresponded to 80 days of growth
($t = 80$) in our *in silico* tumours. As the tumour developed resistance to the
treatment, the dose was released at the time point corresponding to the volume
745 of tumour increasing to approximately 50% of its volume prior to treatment,
which we selected as $t = 210$ in our tumours. A final dose was given after
approximately 30 days of unimpeded growth, at $t = 240$.

6.1. Resistance and re-sensitisation dynamics are captured by plastic, metabolic 750 *in silico* modelling

As is the case with the *in vivo* experiments, we observe the death, tolerance,
and regrowth pattern within the tumour (Fig. 11). This is then followed by a
period of rapid, unimpeded growth due to the removal of drugs from the tumour.
It is important to notice that upon the second wave of treatment, the tumour is
755 again eradicated entirely for some brief period before becoming resistant more

Figure 11: **Resistance and re-sensitisation dynamics are captured by *in silico* modelling.** Graph displaying the tumour volume of the metabolic tumour model over the duration of the *in silico* experiment, with continuous doses given from $t \in \{80, 240\}$ and a drug holiday initiated at $t = 210$

rapidly on this second occasion (Fig. 11). This correlates qualitatively with the *in vivo* results but may not be explained by a mutational model since those resistant cells would not reestablish their sensitivity to treatment. This effect is termed ‘re-sensitisation’ and may be biologically and clinically significant.

760 In order to more accurately capture the results of the biological, experimental approach we use a lower dosing rate in this model. Also, the dose was applied uniformly in time between the start and the end of the treatment, instead of instantaneously (we used Heaviside functions instead of Dirac functions for the drug temporal profiles). This ensured a more gradual switch from the initial
765 growth stage in the tumour to a drug-sensitive apoptotic phase, prior to tolerance (Fig. 11). Moreover, the primary regrowth stage appears to be damped in comparison to the mutational model under BRAFi treatment, alone, but this could be explained by the supplementary dosing of the tumour with MEKi, stunting regrowth to a greater extent.

Figure 12: **Tumours use oxphos metabolic pathways to resist targeted inhibition of glycolytic pathways by BRAFi and MEKi therapies.** Shown are the phenotypic distribution (1st row); the spatio-phenotypic surface distributions (2nd row); and spatial distribution (3rd row) of the cellular population. The spatial distribution of the ECNE, with colour-bar, is also shown (4th row), for completeness and in order that one can place the tumour within its environmental context. All figures are given at times $t \in \{50, 100, 150\}$ within subfigures (a), (b), and (c) respectively. Within the surface plots, the colours represent surfaces of approximately equal concentrations within the spatio-phenotypic context of the cell graduated from lowest to highest concentration as purple, blue, green, then yellow.

770

6.2. Temporary oxphos metabolism may allow cancers to evade targeted treatments

Recall that lower values in y are associated with more glycolytic modes of

Figure 13: **Tumours use oxphos metabolic pathways to resist targeted inhibition of glycolytic pathways by BRAFi and MEKi therapies.** Shown are the phenotypic distribution (1^{st} row); the spatio-phenotypic surface distributions (2^{nd} row); and spatial distribution (3^{rd} row) of the cellular population. The spatial distribution of the ECNE, with colour-bar, is also shown (4^{th} row), for completeness and in order that one can place the tumour within its environmental context. All figures are given at times $t \in \{200, 220, 240\}$ within subfigures (a), (b), and (c) respectively. Within the surface plots, the colours represent surfaces of approximately equal concentrations within the spatio-phenotypic context of the cell graduated from lowest to highest concentration as purple, blue, green, then yellow.

metabolism, where higher values of y are associated with more oxphos modes of metabolism and that each of these structural y -coordinates is associated with a

Figure 14: **Tumours use oxphos metabolic pathways to resist targeted inhibition of glycolytic pathways by BRAFi and MEKi therapies.** Shown are the phenotypic distribution (1^{st} row); the spatio-phenotypic surface distributions (2^{nd} row); and spatial distribution (3^{rd} row) of the cellular population. The spatial distribution of the ECNE, with colour-bar, is also shown (4^{th} row), for completeness and in order that one can place the tumour within its environmental context. All figures are given at times $t \in \{245, 250, 255\}$ within subfigures (a), (b), and (c) respectively. Within the surface plots, the colours represent surfaces of approximately equal concentrations within the spatio-phenotypic context of the cell graduated from lowest to highest concentration as purple, blue, green, then yellow.

2D spatial x -coordinate. Moreover, a *green* encircled 1 in the upper right-hand corner of a graphic shall signify that the tumour is under BRAFi treatment,

Figure 15: **Tumours use oxphos metabolic pathways to resist targeted inhibition of glycolytic pathways by BRAFi and MEKi therapies.** Shown are the phenotypic distribution (1^{st} row); the spatio-phenotypic surface distributions (2^{nd} row); and spatial distribution (3^{rd} row) of the cellular population. The spatial distribution of the ECNE, with colour-bar, is also shown (4^{th} row), for completeness and in order that one can place the tumour within its environmental context. All figures are given at times $t \in \{260, 280, 300\}$ within subfigures (a), (b), and (c) respectively. Within the surface plots, the colours represent surfaces of approximately equal concentrations within the spatio-phenotypic context of the cell graduated from lowest to highest concentration as purple, blue, green, then yellow.

where a *red* encircled 2 in the upper right-hand corner of a graphic shall signify that the tumour is under MEKi treatment (Fig. 12–15).

780 Observe, then, that in the initial growth phase (Fig. 12a) the cell population is tightly associated with a glycolytic metabolic state and that its spatial composition is compact, whilst during the sensitivity phase (Fig. 12b) the cell population begins to diverge from this behaviour and cells may be spatially observed further afield. Moreover, and throughout this phase, one can observe
785 the degeneration of the narrow peak, during the initial growth phase (Fig. 12a, 1st row), into a larger metabolic distribution centred at the same position as this initial peak (Fig. 12b, 1st row). The increase in variance of the metabolic distribution is as a result of the diversification of metabolism under stressed conditions, whereas the displacement of the mean towards a resistant oxphos
790 population (Fig. 12c, 1st row) is as a result of selective pressure.

During the resistance phase, the newly oxphos population continues to proliferate (Fig. 13a), whilst any glycolytic cells are induced to apoptosis. When the drugs are washed from the tumour, however, at $t = 210$ one observes the cellular population beginning to migrate monotonically towards its preferred
795 metabolic state (Fig. 13b, 1st & 2nd rows), ω_c as observed at earlier time points (Fig. 12a, 1st row), before reestablishing its glycolytic phenotype $y \approx \omega_c = 0.2$ at $t = 240$ (Fig. 13c). This whole process is then repeated during the second wave of treatment (Fig. 13c, 14 & 15), with the tumour being visibly eradicated during a process of metabolic diversification and upheaval (Fig. 14b, 14c & 15a)
800 before regrowing as an oxphos oriented tumour (Fig. 15b & 15c).

In this model, one may far more clearly see that the regrowth in the tumour is spatially correlated with the regions of highest ECNE concentrations (Fig. 12c, 3rd & 4th rows) and those regions where the cellular species will necessarily have the greatest access to nutrients. Interestingly, this will also be the spatial
805 subregion in which the selective pressure is most elevated due to the presence of high concentrations of BRAFi+MEKi leading to the apoptosis of glycolytic cells and selecting for a more oxphos-dependent population of cells (Fig. 12c & 13a, 2nd row).

To sum the above analysis of these results, the tumour exhibits an initially
810 glycolytic mode of metabolism which, through stress-induced diversification, de-

cays into a less defined mode of glucose metabolism. By spatially correlating with regions of heightened nutritional content, these resistant oxphos cells are able to outgrow their drug-induced apoptotic rate and proliferate. By removing the drug from the tumour, and the stressor of the cell, the cellular population
815 attempts to reconsolidate its glycolytic state and increases its proliferative rate, ultimately allowing the second wave of treatment to visibly eradicate the remaining population of cells. Nevertheless, these cells are able to regain their metabolic advantage and return to an oxphos state, in order to once again become resistant to treatment.

820

6.3. More rapid secondary resistance wave may be explained by residual oxphos populations

One feature of the growth, which is of great clinical significance, is that of the increased rapidity to resistance upon the second wave of treatment (Fig. 11).
825 In order to understand this, notice the pattern of metabolic migration in the cancer cell population, towards the preferred glycolytic state, during the drug holiday (Fig. 13). The tail on the right-hand side of the oxphos cell distribution (Fig. 13a & 13b, 1st row) are not entirely consolidated during their backwards migration but, rather, remain as a residual oxphos cell population (Fig. 13b,
830 1st row), which begin to appear upon selective degradation of glycolytic populations (Fig. 14b, 1st row). Although these cells will migrate gradually towards their preferred metabolic state, ω_c , it could be that their lower local nutritional value is allowing them to retain their oxphos state to a greater extent than the remainder of the population. Under the selective pressure applied by the drug,
835 the glycolytic subpopulation is degraded, as it again attempts to diversify its metabolic status, whilst the oxphos population is free to grow (Fig. 14b, 14c, & 15, 1st & 2nd rows), eventually replacing the glycolytic population as the dominant population within the tumour (Fig. 15b & 15c).

One may also clearly observe the difference in the spatio-structural distributions 20 days posterior to the first wave of treatment (Fig. 12b, 2nd row) in
840 comparison to 20 days posterior to the second (Fig. 15a, 2nd row). After the

first wave of treatment, the tumour having never been exposed to stress prior to this event, the metabolic profile of the tumour is neatly distributed around its preferred glycolytic state. After the second wave of treatment, however,
845 the metabolic profile is bimodal, with a distinct oxphos as well as a glycolytic population. This appears to be due to the fact that not all of the cells from the resistant oxphos population have migrated fully back to their preferred glycolytic state and are, thus, able to repopulate the new resistant population far more rapidly since they are not subject to the same selective pressures as their
850 glycolytic counterparts.

7. Discussion

We have introduced a general modelling framework for evolution of heterogeneity in solid tumours submitted to multiple drug therapy, wherein the definition of an appropriate normalized structural velocity, $\Psi(y, \bar{m}, \bar{p})$; structural
855 diffusion matrix, $\Sigma(y, \bar{m}, \bar{p})$; growth function, $\Phi_c(y, \bar{m}, c, v)$; and vector valued drug effectiveness function, $\bar{f}(y)$, may give rise to importantly nuanced patterns of behaviour. Using this framework, we then introduced two primary models for considering different dynamics within a tumour population. Firstly, the mutational model considered population level dynamics for a system in which an
860 individual cell will sequentially undergo a BRAF mutation, followed by subsequent mutations which confer resistance to BRAFi and ipilimumab therapies. Secondly, we considered a plastic model of drug resistance, in which the switching of cellular dependence on glycolytic and oxphos pathways for the metabolism of glucose may confer a survival advantage when faced with glycolysis inhibiting
865 BRAFi+MEKi treatments.

Using our mutational model to consider paradigms of punctuated equilibrium and phyletic gradualism in the evolution of the cellular genome, we found that punctuated equilibrium assumptions were more consistent with biological data. This shows good consistency with the modern cancer genomic literature,
870 in asserting that short term catastrophes, rather than the gradual accumulation of mutations, is more likely to contribute to the mutational state of tumours

[47, 48, 49]. We also predicted that using ipilimumab, immune cell-enhancers, in advance of a BRAFi is more effective at reducing the tumour population over the long term. This model prediction is confirmed by studies which used both
875 ipilimumab and BRAFi [26].

Performing experiments for which drug was applied periodically in time we were able to qualitatively recapitulate the results of Thakur *et al.* [27]. We have suggested a mechanism for the apparently counterintuitive result of this experiment, that consists in keeping the tumor under control without completely
880 eliminating the resistant subpopulation. We suggest that relative success of this therapy protocol in some tumours may imply their lesser mutated states at the initiation of the experiment, where the irregularity of the oscillations appears to depend on the number of different clones within or the clonal heterogeneity of the sample. This hypothesis may, presumably, be tested biologically in order
885 to confirm this prediction from our model. The decay of the success of varying treatment strategies within a heterogeneous ECNE is consistent with the *in vivo* failure of treatments to adequately deal with tumours on the long term, and our experiments still predicted the preservation of the characteristic death and growth curves [22] under heterogeneous initial conditions.

890 Turning to the plastic metabolic model for the development of resistance to targeted therapies, we proposed and conformed the ability of such a model to predict re-sensitisation *in silico*. This model may then provide a clinical opportunity to model the success of therapy against such tumours on the basis of their respective environments (i.e. for tumours in differing tissue elasticities
895 or densities). Moreover, our model illustrates the metabolic switching of the tumour as a continually heterogeneous spatio-structural population, allowing one to understand how spatial effects may influence structural resistance manoeuvres. The evolution of the glycolytic tumour to a metabolically oxphos cell populations, in combination with the coincidence of strongly selected cell pop-
900 ulations and nutrient populations, may allow for the resistant proliferation of these subpopulations. These metabolically resistant populations will then preferentially re-sensitise themselves through metabolic remodeling, allowing for the

effective second wave of treatment.

Moreover, our model provides an opportunity to understand the underlying dynamics of such metabolically plastic tumours and also the mechanisms of resistance and re-sensitisation, showing strong agreement with *in vivo* PDX tumour experiments. For both waves of treatment, our model shows a characteristic death, tolerance, and regrowth pattern, but with a quicker relapse occurring with the second wave of treatment. Experiments conducted by Ram-
bow *et al.* [66] also show this pattern of death and growth, with faster regrowth posterior to the second wave of treatment, such that our model may provide an explanation of this phenomenon. Residual, metabolically resistant cells from the first wave of treatment may provide a basis for a resistant population to grow back more quickly upon the second wave of treatment. Implicitly, our model
would predict that reducing treatment to as great an extent as is possible, whilst still eradicating the tumour, would reduce the opportunity for the tumour to establish this residual population and resist future waves of treatment.

Appendix A. Thorough Discussion and Justification of the Mathematical Model

Current modelling approaches consider the cell as a discretely changing variable who exists in an explicitly sensitive or resistant state. We wish, here, to conceive of the cell as a continuously changing and finely tunable evolutionary population. Different cancer cells have similar, if not identical, origins and are not innately differentiable but have rather gained different characteristics.
Therefore, we introduce a novel modelling framework in order to reconceive the mathematical representation of the cell, from this more nuanced perspective.

Cells do, however, function differently. Within these categories, then, there must be a wealth of diversity to reflect the reality of the structural differences between cells. In order to reflect this, we incorporate a term that operates similarly to those structural models previously employed [5, 6], whilst building

on the solid mathematical derivation given by existing spatio-structuro-temporal models [9, 11]. Letting $\mathcal{I} := [0, T] \subset \mathbb{R}_+$ be the time interval over which the experiment is conducted; $\mathcal{D} := [0, 1]^2 \subset \mathbb{R}_+^2$ be the spatial domain; and $\mathcal{P} := [0, 1] \subset \mathbb{R}_+$ define the continuous domain over which the mutational or metabolic changes may occur, we couple these dynamics using a simple conservation of mass assumption. If $V \times W \subseteq \mathcal{D} \times \mathcal{P}$ is an arbitrary volume of the spatio-structural domain with piecewise smooth boundaries ∂V and ∂W respectively, then we can write that the total population of cells in this volume is given by

$$c(t)_{V \times W} = \int_W \int_V c(t, x, y) dx dy. \quad (\text{A.1})$$

Then we can use an existing mathematical framework [9, 11] to deduce that the change in cell density $c(t, x, y)$ is given by the partial differential equation

$$\frac{\partial}{\partial t} c(t, x, y) = \underbrace{\nabla_x \cdot F(c, v, \bar{m})}_{\text{Spatial Flux}} + \underbrace{\nabla_y G(y, c, v, \bar{m}, \bar{p})}_{\text{Structural Flux}} + \underbrace{S(y, c, v, \bar{m}, \bar{p})}_{\text{Source}}. \quad (\text{A.2})$$

Let $\Psi(y, \bar{m}, \bar{p}) : \mathcal{I} \times \mathcal{D} \times \mathcal{P} \rightarrow \mathbb{R}$ be the normalized structural velocity for the cellular population. During a time interval of small length Δt , those cells having the mutational or metabolic state y initially at t , will evolve to a state $y + r_\mu \Psi(y, \bar{m}, \bar{p}) \Delta t$ at $t + \Delta t$, where r_μ is the mean mutation rate. Moreover, let $\Sigma(y, \bar{m}, \bar{p}) : \mathcal{I} \times \mathcal{D} \times \mathcal{P}$ be the structural diffusion matrix for the cellular population. Hence, the structural flux reads

$$\begin{aligned} G(y, c, v, \bar{m}, \bar{p}) &= G_a(y, c, v, \bar{m}, \bar{p}) + G_d(y, c, v, \bar{m}, \bar{p}), \\ G_a(y, c, v, \bar{m}, \bar{p}) &= r_\mu \Psi(y, \bar{m}, \bar{p}) c(t, x, y), \\ G_d(y, c, v, \bar{m}, \bar{p}) &= -\Sigma(y, \bar{m}, \bar{p}) \nabla_y c(t, x, y). \end{aligned} \quad (\text{A.3})$$

With this concept of a continuum of phenotypic progression, we then recognise that pharmaceuticals are generally targeted at specific metabolic pathways (related to selected cancer-related phenotypes and their respectively triggered mechanisms). Therefore, we employ a description of a phenotypic 'spectrum' wherein cells may inhabit any point on that available spectrum in y . These drugs may then target specific regions on this spectrum which employ the molecular

pathways inhibited by these drugs. For this we form an effectiveness vector
 955 $\bar{f}(y) \in \mathcal{Y}^P$ which describes the bandwidth in the mutational dimension $\mathcal{P}$ on
 which the drug is effective at diminishing the population of cells, for each given
 drug, p_j , $j \in \{0, \dots, P\}$.

Appendix A.1. Discussion on Single-Dosage Systems

960 The choice of mutational rate of change function would have to accurately
 represent the most sensible possible case for PG and PE, respectively. From
 (A.3) it is clear that the no-flux boundary condition is fulfilled automatically if
 the structural velocity satisfies

$$\Psi(\tilde{y}, \bar{m}, \bar{p}) = 0, \quad \forall \tilde{y} \in \partial\mathcal{P},$$

where $\partial\mathcal{P}$ is the boundary of the structural domain $\mathcal{P}$.

965 The structural velocity for PG is considered to be constant, except for a
 small region at the boundary. In order to construct such a function, we start
 with

$$\hat{\Psi}_g(y, \bar{m}, \bar{p}) := 1 - \sum_{i=0}^1 \left(1 + \exp \left[-\beta_g \left((2y-1)i - y + \frac{5}{\beta_g} \right) \right] \right)^{-1}, \quad (\text{A.4})$$

where β_g is chosen sufficiently large such that the function $\hat{\Psi}_g(y, \bar{m}, \bar{p})$ is close
 to one everywhere except at narrow neighborhoods of $y = 0$ and of $y = 1$. The
 970 symmetry of the function $\hat{\Psi}_g$ implies that no-flux boundary conditions can be
 achieved by the imposition of

$$\Psi_g(y, \bar{m}, \bar{p}) := \psi_g \left(\hat{\Psi}_g(y, \bar{m}, \bar{p}) - c_g \right),$$

where the lower case ψ_g gives the mutation rate parameter and $c_g := \hat{\Psi}_g(0, \bar{m}, \bar{p}) =$
 $\hat{\Psi}_g(1, \bar{m}, \bar{p})$ (Fig. 2a).

For the PE function, one must consider several features. Beyond smoothness,
 975 that is needed for both technical and biological reasons, one must again satisfy

the no-flux conditions and impose the further conditions

$$\begin{aligned} \frac{\partial^2}{\partial y^2} \Psi_e(y, \bar{m}, \bar{p}) \Big|_{y=\frac{1}{2}} &> 0, & \frac{\partial^2}{\partial y^2} \Psi_e(y, \bar{m}, \bar{p}) \Big|_{y=\{\frac{1}{4}, \frac{3}{4}\}} &< 0, \\ \frac{\partial}{\partial y} \Psi_e(y, \bar{m}, \bar{p}) \Big|_{y=\{\frac{1}{4}, \frac{1}{2}, \frac{3}{4}\}} &= 0 \end{aligned} \quad (\text{A.5})$$

which is to say that maximal mutational velocity should occur between points of phyletic stability, "equilibria", and minimal velocity should occur at intermediate points of phyletic stability (where boundary conditions cover the cases of minimal and maximal phyletic deviance). Thus, one can choose a function of the form

$$\hat{\Psi}_e(y, \bar{m}, \bar{p}) := \frac{1}{2} \left(1 - \cos \left(2\pi \hat{N}_\psi y \right) \right) + \alpha_g \sum_{i=1}^{N_\psi-1} \exp \left[-\beta_e \left(y - \frac{i}{N_\psi} \right) \right], \quad (\text{A.6})$$

where $N_\psi = 3$ is the number of absolute mutational states in the considered paradigm (pre-mutated, BRAF mutated, & resistantly mutated); β_e is chosen such that distribution is increased smoothly; and the symmetry of this function in the domain implies that the no-flux boundary conditions can be satisfied by imposing

$$\Psi_e(y, \bar{m}, \bar{p}) := \psi_e \left(\hat{\Psi}_e(y, \bar{m}, \bar{p}) - c_e \right), \quad (\text{A.7})$$

where ψ_e again gives the mutational rate and $c_e := \hat{\Psi}_e(0, \bar{m}, \bar{p}) = \hat{\Psi}_e(1, \bar{m}, \bar{p})$ (Fig. 2b).

Defining the cancerous population as being represented by a continuous distribution in the mutational space further allows one to define the drug effectiveness functions such that the drugs themselves target, not a discrete subset of the cellular population but rather, a continuous distribution of phenotypes which correspond to states in $\mathcal{P}$. With this in mind, we begin by defining the function itself as being represented by a vector of such distributions, each distribution describing the action of an individual drug

$$\mathbf{f}(y) := [\mathbf{f}_1(y), \mathbf{f}_2(y)]^T.$$

Then, we can continue by defining the individual effectiveness functions of each

drug as being given by the standard Gaussian distribution in y , such that

$$\begin{cases} f_1(y) := \exp[-\beta_{f_1}(y - \alpha_{f_1})^2] \\ f_2(y) := \exp[-\beta_{f_2}(y - \alpha_{f_2})^2], \end{cases} \quad (\text{A.8})$$

where β_{f_1}, β_{f_2} define, reciprocally, the breadth of the distribution and $\alpha_{f_1}, \alpha_{f_2}$ define the mutational position, in y , of maximal effectiveness.

1000 In this case, since we consider $N_\psi = 3$ mutationally-equidistant resting states for the tumour population, we define that the BRAF inhibitor, p_1 , targets a mutational state which corresponds to the most susceptible of these resting (low relative mutational rate) states, $\alpha_{f_1} = \frac{1}{2}$. In this sense, also, we assert that the resting state, α_{f_1} , represents a mutational state wherein the cell has
1005 a BRAF mutation, which makes cells in this state most susceptible to BRAFi treatment.

We then make a phenomenological choice, although with some support from the existing literature, to maximise the effectiveness of drug p_2 , i.e. ipilimumab, at an arbitrary position between the establishment of mutational states corresponding to $y' \in \{\frac{1}{2}, 1\}$, such that $\alpha_{f_2} \approx \frac{3}{4}$. We interpret the choice of α_{f_1}
1010 (smaller than α_{f_2}) as conveying the sense that BRAFi is maximally responsive at early mutational states where PTEN mutation is developing but not established within the population, whereas ipilumab is maximally responsive at later stages. We assume this on the basis that treatment with BRAFi, prior to
1015 treatment with immune cell enhancers, is ineffective as opposed to the contrary and that this implies that sensitivity to BRAFi may occur at an early stage of mutational development.

Appendix A.2. Discussion on Multi-Dosage Systems

1020 Thusly, we describe the metabolic change function, $\Psi : \mathcal{D} \times \mathcal{P} \rightarrow \mathbb{R}$, in terms of the phenotypic stress on the cell. We assume, firstly, that under a condition in which the influence of stressors is minimised, the cell has a preferred phenotypic state at $y = \omega_c$, which corresponds to a given utilisation of each pathway. We also assume that the primary stressors for the cell are malnutrition, which will

1025 be a function of m_2 , the presence of BRAFi, p_1 , and that of MEKi, p_2 , which
act to deplete the cells ability to proliferate effectively.

Then the non-stressed term in the function must be given such that pheno-
typic advection is positive below this preferential state and negative above this
state such that it will depend upon the relation $1 - \omega_c$ for a non-dimensionalised
1030 system. The non-stressed condition must then be given by the opposing prob-
ability to that of stress such that $\Psi_{\bar{\sigma}} := 1 - \psi_{p_1}p_1 - \psi_{p_2}p_2$, with parameters
chosen such that $\Psi_{\bar{\sigma}} \geq 0, \forall(t, x) \in \mathcal{I} \times \mathcal{D}$.

Stressed conditions for the cell are then quantified by the gradient of the
cellular concentration in the region, giving a measurement of the collectivity of
1035 the behaviours of local cells. This choice of function for stressed conditions gives
rise to diffusion under cellular stress, the rationale for which can be given by the
intuitive understanding that cells diversify their behaviours in the presence of
stressors. The magnitude of this stress is then determined by the concentrations
of BRAFi, p_1 , and MEKi, p_2 , and is linearly diminished with the concentration
1040 of nutrient species, m_2 . All of these factors act as stressors to the cell and have
their relative effects quantified by the weights $\psi_{p_1}, \psi_{p_2}, \psi_{m_2} \geq 0$, respectively.
Then, the structural flux has diffusion and advection terms as follows

$$\begin{aligned} \Psi_M(y, \bar{m}, \bar{p}) := & -\sigma_c (\psi_{p_1}p_1 + \psi_{p_2}p_2 - \psi_{m_2}m_2) \nabla_y c(t, x, y) \\ & + \bar{\sigma}_c (\omega_c - y) (1 - \psi_{p_1}p_1 - \psi_{p_2}p_2) c(t, x, y), \end{aligned} \quad (\text{A.9})$$

with the introduction of the stress, σ_c , and non-stress, $\bar{\sigma}_c$, parameters deter-
mining the weightings of the diffusion and advection terms with respect to one
1045 another.

Now, one must consider the nature and form of the effectiveness functions
for the drug species, BRAFi (p_1) and MEKi (p_2), on the cellular population, in
terms of their effect on the glycolytic or oxphos pathways. Firstly, we begin by
writing the vector

$$\mathbf{f}(y) := [\mathbf{f}_1(y), \mathbf{f}_2(y)]^T,$$

1050 to represent functions $\mathbf{f}_1(y)$ and $\mathbf{f}_2(y)$ in compact notation and begin by noticing
that both of these drugs target genes essential to glycolysis. The transcription

factors HIF1 α , c-Myc, and Mondo A have been found to be downstream upregulators of glycolytic behaviours in BRAF^{v600} cells [67, 71]. Moreover, BRAFi has been shown to prevent the hyperswitching of mutant melanoma cells to
1055 pyruvate based metabolism [72] – the primary product of glycolysis.

Withal, MEKi is responsible for targeting this same pathway, in melanoma cells. It has also been found that the PI3K pathway, activated by MEK, is responsible for glucose transport, and glycolytic metabolism, and can be inhibited by inhibition of MEK [73, 74].

1060 The biological literature points to a link between melanoma associated genes, including BRAF and MEK, and the glycolytic pathway for glucose metabolism. Therefore, we write that the standard forms of the effectiveness functions will be Gaussian functions, with low values for variance, or high values for β_{f_1} and β_{f_2} , such that

$$\begin{cases} f_1(y) := \exp[-\beta_{f_1}(y - \alpha_{f_1})^2] \\ f_2(y) := \exp[-\beta_{f_2}(y - \alpha_{f_2})^2]. \end{cases} \quad (\text{A.10})$$

1065 The values around which these functions are centred, $\alpha_{f_1} < \frac{1}{2}$ and $\alpha_{f_2} < \frac{1}{2}$, are chosen to align with the peak effect of the drug on the glycolytic and oxphos pathways.

Finally, we choose the proliferation function, $\phi_M : \mathcal{I} \times \mathcal{D} \times \mathcal{P} \rightarrow \mathbb{R}$, such that it is space-wise logistic in $c(t, x, y)$. Moreover, we assume that the cellular pop-
1070 ulation requires nutrient in order to achieve positive proliferation and choose some arbitrary threshold value θ_{m_2} in order that, below such a value, the cellular population is depleted due to malnutrition. It is then imposed upon the system that there are two concurrent modes of proliferation: glycolytic and non-glycolytic. The non-glycolytic mode is not dependent upon the phenotypic state
1075 of the cell, y , and is rather an underlying process of all cells, whereas the glycolytic pathway is linearly enhanced by the percentage of glycolytic metabolism utilised (such that it is maximal at $y = 0$). This is justified on account of the excess lipids produced through utilisation of glycolytic pathways. Therefore, we

	c	v	m_1	m_2	p
D	1×10^{-5}		1×10^{-4}	1×10^{-4}	5×10^{-4}
ϕ	0.4	5×10^{-2}	0.1	0.1	
δ	2	10	0.1	5×10^{-2}	5×10^{-2}
χ		5×10^{-5}	1×10^{-3}	0	0

Table B.1: List of parameters used for numerical simulations of the model. Parameters are defined within a non-dimensionalised system (excepting for time measured in days) and, as such, are defined in terms of units days^{-1} .

write

$$\phi_M(y, c, \bar{m}) := c \left(1 - \int_{\mathcal{P}} c(t, x, y) dy \right) \left(m_2 - \theta_{m_2} \right) \left(\phi_{c,1} + \phi_{c,2}[1 - y] \right), \quad (\text{A.11})$$

where $\phi_{c,1}$ and $\phi_{c,2}$ give the rates of non-glycolytic and glycolytic metabolism, respectively.

Appendix B. Numerical Methods

Appendix B.1. Methods for Mutational, Single-Dosage System

Initial conditions were chosen to be consistent with previous models [53] and for consistency with the biological methodology, as regards the impregnation of mice with cancerous cells. The particular study, using animal models, with which we compare our results injected mice with approximately $5 \times 10^3 - 2 \times 10^5$ cells [75]. Therefore, our initial conditions reflect this with

$$c_0 = \exp \left[-50(x^2 + 8 \cdot (y - \eta)^2) \right] \quad \text{such that} \quad \iint_{\mathcal{D}} \int_{\mathcal{P}} c_0(t, x, y) dx dy \approx 1 \times 10^8, \quad (\text{B.1})$$

where, since we know that the biological experiments were initiated with an approximate cell count of 2.5×10^4 cells, we assume that the cellular distribution is measured approximately in 10^3 cells unit_x^{-2} . Further, the default initial

location in the phenotypic dimension is given by $\eta = \frac{1}{50}$. One should also clarify
1095 that this constitutes not an entirely pre-mutated cell population but an already
heterogeneous mixture of cells with at least one precursor event that induces
the early stages of the BRAF mutation process.

Other quantities for which it is imperative that one have measures include
the gross spatial population, which is given by the cellular population taken
1100 over the entirety of the structure domain, $\mathcal{P}$, and is given by

$$C(t, x) := \int_{\mathcal{P}} c(t, x, y) dy. \quad (\text{B.2})$$

To calculate the volume of their tumour from its 2-dimensional section, Perna
et al. [22] measure the lengths of the major and minor axes of the visible tumour,
given by a and b respectively, and use the formula of an ellipsoid to write

$$V = \frac{4\pi}{3} \frac{a}{2} \frac{b}{2} \frac{b}{2} = \frac{\pi}{6} abb \quad (\text{B.3})$$

In order to avoid having to define the value of our function, $c(t, x, y)$, above
1105 which the tumour would constitute a visible tumour, which would otherwise be
given by a threshold of visibility θ_v , we assume the proportionality of the tumour
mass and the area of the section over which the tumour is visible, written as

$$\iint_{\mathcal{D}} \int_{\theta_y}^1 c(t, x, y) dy dx \approx k(\theta_v) \iint_{\mathcal{D}} \mathbb{1}_{\left\{ \int_{\theta_y}^1 c(t, x, y) dy \geq \theta_v \right\}} dx, \quad (\text{B.4})$$

where the proportionality constant is dependent on the visibility threshold and
is given by $k : \mathbb{R} \rightarrow \mathbb{R}$. To calculate the model's tumour volume, i.e. the volume
1110 of cells which have developed into cancerous subtypes, we then take the mass
of the tumour at $y \geq \theta_y$ and invoke the calculation from the tuning model [22]
such that

$$V_c := K \sqrt{\left(\iint_{\mathcal{D}} \int_{\theta_y}^1 c(t, x, y) dx dy \right)^3}, \quad (\text{B.5})$$

with the adaptation of the ellipsoidal volume equation to $V = \frac{\pi}{6} ab\sqrt{ab}$ and
where we take that $\theta_y = 0.2$ and K is an arbitrary constant.

1115 Then, in order to carry out our test experiment, we control the heterogeneity using the following formula for the initial condition

$$c_0 := \sum_{j=1}^J \exp \left[- \left(x^2 + (y - \eta_j)^2 \right) \right], \quad \eta_j \in (0, 0.5], \forall j \in \{1, \dots, J\}$$

and also in line with the initial volume condition (B.1), and where J is in some sense a measure of the initial heterogeneity. We then apply the drug dosage periodically in time intervals given by $[0, 20] \cup [40, 60] \cup [80, 100] \cup [120, 140]$. For 1120 the simulations given in this current study, we use the range $J \in \{1, \dots, 5\}$ to establish example data.

Appendix B.2. Methods for Metabolic, Multi-Dosage Systems

Due to the nature of the structural flux (A.9), it is necessary to develop a 1125 set of zero-flux boundary conditions which prevent, for example, diffusion in y from causing cells to exit the domain, $\mathcal{P}$. Although (A.9) has both advection and diffusion terms, the metabolic change function is defined such that $\Psi_{\bar{\sigma}}(y) = 0$, $y \in \partial\mathcal{P}$, meaning that advection fluxes are identically zero on the boundary. Therefore, we simply implement zero-Neumann boundary conditions 1130 on structural diffusion fluxes, namely $\nabla_y c(t, x, y) = 0$, $y \in \partial\mathcal{P}$.

To begin treatment, one gradual dosage was given between $t = 80$ and $t = 100$, linearly in time, t . The drug was then washed from the tumour, in a step-wise fashion, at $t = 210$, as this is the point at which the tumour volume had regrown to $\sim 20\%$ of its previous maximum, and the tumour was allowed to 1135 regrow, unencumbered by glycolytic inhibitors for 30 days. A second gradual dosage was then given between $t = 240$ and $t = 260$, whereafter no further interventions were made.

Further, we define the unique structured population profile by the cellular population over the entirety of the spatial domain, $\mathcal{D}$, given by

$$\hat{C}(t, y) := \iint_{\mathcal{D}} c(t, x, y) d\mathbf{x}. \quad (\text{B.6})$$

1140 This can be used to describe the metabolic or structural profile of the tumour at a given time, t .

Acknowledgements

The authors gratefully acknowledge financial support from the Canceropole GSO and École Doctorale I2S de l'Université de Montpellier. We are also grateful to N. Theret, A. Devenyi, and D. Fisher for their critical reading of the manuscript.

References

- [1] Humplik J, Hill AL, Nowak MA. Evolutionary dynamics of infectious diseases in finite populations. *Journal of Theoretical Biology* 2014;360:149–62.
- 1150 [2] Ghang W, Nowak MA. Stochastic evolution of staying together. *Journal of Theoretical Biology* 2014;360:129–36.
- [3] Bozic I, Nowak MA. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. *Proceedings of the National Academy of Sciences of the United States of America* 2014;111(45):15964–
1155 8.
- [4] Kleinman A. The mathematics of random mutation and natural selection for multiple simultaneous selection pressures and the evolution of antimicrobial drug resistance. *Statistics in Medicine* 2016;35(29):5391–400.
- 1160 [5] Lorz A, Lorenzi T, Hochberg ME, Clairambault J, Perthame B. Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapy. *ESAIM: Mathematical Modelling and Numerical Analysis* 2012;47:377–99.
- 1165 [6] Lorz A, Lorenzi T, Clairambault J, Escargueil A, Perthame B. Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors. *Bulletin of Mathematical Biology* 2015;77(1):1–22.

- [7] Eldredge N, Gould SJ. Models in Paleobiology; chap. 5. Punctuated Equilibria: An Alternative to Phyletic Gradualism. Freeman, Cooper and Company; 1972, p. 82–115.
- 1170 [8] Waclaw B. Evolution of drug resistance in bacteria. *Advances and Medicine and Biology* 2016;915:49–67.
- [9] Domschke P, Trucu D, Gerisch A, Chaplain MAJ. Structured models of cell migration incorporating molecular binding processes. *Journal of Mathematical Biology* 2017;75(6-7):1517–61.
- 1175 [10] Hodgkinson A, Chaplain MAJ, Domschke P, Trucu D. Computational approaches and analysis for a spatio-structural-temporal invasive carcinoma model. *Bulletin of Mathematical Biology* 2018;doi:\bibinfo{doi}{https://doi.org/10.1007/s11538-018-0396-4}.
- [11] Hodgkinson A, Radulescu O, Uzé G, Trucu D. Signal propagation in sensing and reciprocating cellular systems with spatial and structural heterogeneity. *Bulletin of Mathematical Biology* 2018;:(*accepted*).
- 1180 [12] Gatenby RA, Gawlinski ET. A Reaction-Diffusion Model of Cancer Invasion. *Cancer Res* 1996;56(24):5745–53.
- [13] Chaplain MAJ, Lolas G. Mathematical modelling of cancer invasion of tissue: Dynamic heterogeneity. *Networks and Heterogeneous Media* 2006;1(3):399–439.
- 1185 [14] Jang S, Atkins MB. Which drug, And when, For patients with BRAF-mutant melanoma? *The Lancet Oncology* 2013;14(2):e60–9.
- [15] Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* 2010;467:596–9.
- 1190 [16] Paraiso KHT, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. *Cancer Research* 2011;71(7):2750–60.

- 1195 [17] Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK,
et al. Recovery of phospho-ERK activity allows melanoma cells to escape
from BRAF inhibitor therapy. *Br J Cancer* 2010;102(12):1724–30.
- [18] Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A,
et al. Incidence of the V600K mutation among melanoma patients with
1200 BRAF mutations, and potential therapeutic response to the specific BRAF
inhibitor PLX4032. *Journal of translational medicine* 2010;8:67.
- [19] Smalley KSM, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, et al.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in
BRAF V600E-mutated melanomas. *Mol Cancer Ther* 2008;7(9):2876–83.
- 1205 [20] Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-
Penton A, et al. Systematic identification of signaling pathways with poten-
tial to confer anticancer drug resistance. *Science Signalling* 2015;57(6):742–
68.
- [21] Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, et al. A new
1210 water soluble MAPK activator exerts antitumor activity in melanoma cells
resistant to the BRAF inhibitor vemurafenib. *Biochemical Pharmacology*
2014;95(1):16–27.
- [22] Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F,
et al. BRAF inhibitor resistance mediated by the AKT pathway in an
1215 oncogenic BRAF mouse melanoma model. *Proceedings of the National
Academy of Sciences of the United States of America* 2015;112(6):E536–
45.
- [23] Villanueva J, Infante JR, Krepler C, Reyes-Urbe P, Samanta M, Chen
HY, et al. Concurrent MEK2 Mutation and BRAF Amplification Con-
1220 fer Resistance to BRAF and MEK Inhibitors in Melanoma. *Cell Reports*
2013;4(6):1090–9.

- [24] Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discovery* 2014;4(1):69–79.
- 1225 [25] Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. *Cancer* 2014;120(11):1695–701.
- 1230 [26] Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, et al. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. *Journal of Clinical Oncology* 2012;30:8569–.
- 1235 [27] Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. *Nature* 2013;494(7436):251–5.
- [28] Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to b-raf(v600e) inhibition by rtk or n-ras upregulation. *Nature* 2010;468:973–7.
- 1240 [29] Alcalá AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: Clinical trials and mechanisms of resistance. *Clinical Cancer Research* 2012;18(1):33–9.
- 1245 [30] Slipicevic A, Holm R, Nguyen MTP, Böhler PJ, Davidson B, Flørenes VA. Expression of activated Akt and PTEN in malignant Melanomas: Relationship with clinical outcome. *American Journal of Clinical Pathology* 2005;124(4):528–36.
- [31] Kamo N, Ke B, Busuttil RW, Kupiec-Weglinski JW. PTEN-mediated akt/b-Catenin/foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury. *Hepatology* 2013;57(1):289–98.

- [32] Ouyang W, Beckett O, Flavell RA, Li MO. An Essential Role of the Forkhead-Box Transcription Factor Foxo1 in Control of T Cell Homeostasis and Tolerance. *Immunity* 2009;30(3):358–71.
- [33] Kim M, Ouyang W, Liao W, Zhang M, Li M. The transcription factor foxo1 controls central-memory CD8+ T cell responses to infection. *Immunity* 2013;39(2):286–97.
- [34] Hess Michelini R, Doedens AL, Goldrath AW, Hedrick SM. Differentiation of CD8 memory T cells depends on Foxo1. *The Journal of experimental medicine* 2013;210(6):1189–200.
- [35] Günzl P, Schabbauer G. Recent advances in the genetic analysis of PTEN and PI3K innate immune properties. *Immunobiology* 2008;213(9-10):759–65.
- [36] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417(6892):949–54.
- [37] Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Eng J Med* 2011;364(26):2507–16.
- [38] Goel VK, Lazar AJF, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. *J Invest Dermatol* 2006;126(1):154–60.
- [39] Darwin C. *On the Origin of Species by Means of Natural Selection*. John Murray; 1859.
- [40] Dawkins R, Krebs JR. Arms races between and within species. *Proceedings of the Royal Society B* 1979;205(1161).
- [41] Mayr E. *Change of genetic environment and evolution*. 1954.

- [42] Lieberman BS, Eldredge N. What is punctuated equilibrium? What is
1275 macroevolution? A response to Pennell et al. *Trends in Ecology and Evolution* 2014;29(4):185–6.
- [43] Knudson AG. Mutation and cancer: statistical study of retinoblastoma. *Proceedings of the National Academy of Sciences* 1971;68(4):820–3.
- [44] Cairns J. Mutation selection and the natural history of cancer. *Nature*
1280 1975;255(5505):197.
- [45] Nowell PC. The clonal evolution of tumor cell populations. *Science* 1976;194(4260):23–8.
- [46] Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. *British journal of cancer* 1954;8(1):1.
- [47] Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* 2011;144:27–40.
1285
- [48] Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single chromosomes. *Cell* 2011;144(1):9–10.
- [49] Shen M. Chromoplexy: A New Category of Complex Rearrangements in the Cancer Genome. *Cancer Cell* 2013;23(5):567–9.
1290
- [50] Cross WCH, Graham TA, Wright NA. New paradigms in clonal evolution: punctuated equilibrium in cancer. *Journal of Pathology* 2016;240(2):126–36.
- [51] Sato F, Saji S, Toi M. Genomic tumor evolution of breast cancer. *Breast Cancer* 2016;23(1):4–11.
1295
- [52] Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. *Nature* 2016;538(7625):378–82.

- 1300 [53] Beckman RA, Schemmann GS, Yeang CH. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. *Proceedings of the National Academy of Sciences* 2012;109(36):14586–91.
- [54] Melchor L, Brioli A, Wardell C, Murison A, Potter N, Kaiser M, et al. 1305 Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. *Leukemia* 2014;28(8):1705.
- [55] McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. *Cancer Cell* 2015;12:15–26.
- 1310 [56] Davis A, Gao R, Navin N. Tumor Evolution: Linear, Branching, Neutral or Punctuated? *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* 2017;.
- [57] Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. *Cell* 2012;150:251–63.
- 1315 [58] Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. *Nature* 2013;501:338–45.
- [59] Das Thakur M, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. *Cancer Research* 2013;73(20):6106–11.
- 1320 [60] Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. *The New England Journal of Medicine* 2015;373(20):1926–36.
- [61] Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to raf inhibition in 1325 metastatic melanoma. *Cancer Discovery* 2014;4:94–109.

- [62] Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. Map kinase pathway alterations in braf-mutant melanoma patients with acquired resistance to combined raf/mek inhibition. *Cancer Discovery* 2014;4:61–8.
- 1330 [63] Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. *Cancer Cell* 2009;15(4):294–303.
- [64] Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-
1335 induced mouse model of melanoma. *Cell* 2011;147(2):382–95.
- [65] Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. *Nature Reviews Drug Discovery* 2012;11(11):873–86.
- [66] Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M,
1340 et al. Toward minimal residual disease-directed therapy in melanoma. *Cell* 2018;174(4):843–55.
- [67] Parmenter TJ, Kleinschmidt M, Kathryn M. Kinross , Bond ST, Li J, Kaadige MR, et al. Response of braf mutant melanoma to braf inhibition is mediated by a network of transcriptional regulators of glycolysis. *Cancer
1345 Discovery* 2014;4(4):423–33. NIHMS150003.
- [68] Bosc C, Selak MA, Sarry JE. Resistance is futile: Targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. *Cell Metabolism* 2017;26:705–7.
- [69] Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC,
1350 et al. Oncogenic braf regulates oxidative metabolism via pgc1a and mitf. *Cancer Cell* 2013;23:302–15.
- [70] Warburg O. On the origin of cancer cells. *Science* 1956;123(3191):309–14.

- [71] Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, et al. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. Scientific Reports 2017;7(October 2016):42604. 1355
- [72] Delgado-Goni T, Miniotti MF, Wantuch S, Parkes HG, Marais R, Workman P, et al. Cancer Biology and Signal Transduction The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells. Molecular Cancer Therapeutics 2016;15(12):2987–99. 1360
- [73] Través PG, de Atauri P, Marin S, Pimentel-Santillana M, Rodriguez-Prados JC, Marin de Mas I, et al. Relevance of the MEK/ERK Signaling Pathway in the Metabolism of Activated Macrophages: A Metabolomic Approach. The Journal of Immunology 2012;188(3):1402–10. 1365
- [74] Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, et al. Signaling through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. Journal of Biological Chemistry 2015;290(28):17495–504. 1370
- [75] Hata RI, Izukuri K, Kato Y, Sasaki S, Mukaida N, Maehata Y, et al. Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice. Scientific Reports 2015;5:9083. 1375